Thrombosis
Volume 2010 (2010), Article ID 908272, 6 pages
doi:10.1155/2010/908272
Research Article

The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses

Alex R. Hobson,1 Zeshan Qureshi,2 Phil Banks,3 and Nicholas Curzen2,3

1Cardiac Intervention Unit, Royal Bournemouth Hospital, Castle Lane East, Bournemouth, BH7 7DW, UK
2Wessex Cardiothoracic Unit, Southampton University Hospital, Tremona Road, SO16 6YD, UK
3Southampton University Medical School, Southampton University Hospital, Tremona Road, Southampton, SO16 6YD, UK

Received 4 July 2009; Accepted 14 August 2009

Academic Editor: Karin Przyklenk

Copyright © 2010 Alex R. Hobson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Gurbel, K. P. Bliden, K. M. Hayes, J. A. Yoho, W. R. Herzog, and U. S. Tantry, “The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting,” Journal of the American College of Cardiology, vol. 45, no. 9, pp. 1392–1396, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. D. J. Angiolillo, A. Fernández-Ortiz, E. Bernardo, et al., “High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability,” European Heart Journal, vol. 25, no. 21, pp. 1903–1910, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. G. Patti, G. Colonna, V. Pasceri, L. L. Pepe, A. Montinaro, and G. Di Sciascio, “Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study,” Circulation, vol. 111, no. 16, pp. 2099–2106, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. T. Cuisset, C. Frere, J. Quilici, et al., “Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting,” Journal of the American College of Cardiology, vol. 48, no. 7, pp. 1339–1345, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. G. Montalescot, G. Sideris, C. Meuleman, et al., “A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial,” Journal of the American College of Cardiology, vol. 48, no. 5, pp. 931–938, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. N. Von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schömig, A. Kastrati, and A. Schömig, “Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial,” Circulation, vol. 112, no. 19, pp. 2946–2950, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. J. Price, J. L. Coleman, S. R. Steinhubl, G. B. Wong, C. P. Cannon, and P. S. Teirstein, “Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers,” American Journal of Cardiology, vol. 98, no. 5, pp. 681–684, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. S. Matetzky, B. Shenkman, V. Guetta, et al., “Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction,” Circulation, vol. 109, no. 25, pp. 3171–3175, 2004. View at Scopus
  9. P. A. Gurbel, K. P. Bliden, K. Guyer, et al., “Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1820–1826, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. T. Geisler, H. Langer, M. Wydymus, et al., “Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation,” European Heart Journal, vol. 27, no. 20, pp. 2420–2425, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. P. A. Gurbel, K. P. Bliden, W. Samara, et al., “Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1827–1832, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. P. Buonamici, R. Marcucci, A. Migliorini, et al., “Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis,” Journal of the American College of Cardiology, vol. 49, no. 24, pp. 2312–2317, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. Wenaweser, J. Dörffler-Melly, K. Imboden, et al., “Stent thrombosis is associated with an impaired response to antiplatelet therapy,” Journal of the American College of Cardiology, vol. 45, no. 11, pp. 1748–1752, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. R. Hobson, G. Petley, G. Morton, K. D. Dawkins, and N. P. Curzen, “Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy,” Thrombosis Journal, vol. 6, article 1, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. R. Hobson, G. W. Petley, K. D. Dawkins, and N. Curzen, “A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography,” Platelets, vol. 18, no. 7, pp. 497–505, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. R. M. Craft, J. J. Chavez, S. J. Bresee, D. C. Wortham, E. Cohen, and R. C. Carroll, “A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation,” The Journal of Laboratory and Clinical Medicine, vol. 143, no. 5, pp. 301–309, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. R. A. Swallow, R. A. Agarwala, K. D. Dawkins, and N. P. Curzen, “Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?” Platelets, vol. 17, no. 6, pp. 385–392, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. C. Frere, T. Cuisset, J. Quilici, et al., “ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome,” Thrombosis and Haemostasis, vol. 98, no. 4, pp. 838–843, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Neubauer, S. Lask, A. Engelhardt, and A. Mügge, “How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification,” Thrombosis and Haemostasis, vol. 99, no. 2, pp. 357–362, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. D. J. Angiolillo, S. B. Shoemaker, B. Desai, et al., “Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study,” Circulation, vol. 115, no. 6, pp. 708–716, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. A. Jakubowski, C. D. Payne, Y. G. Li, et al., “The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration,” Thrombosis and Haemostasis, vol. 99, no. 2, pp. 409–415, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. L. Bonello, L. Camoin-Jau, S. Arques, et al., “Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study,” Journal of the American College of Cardiology, vol. 51, no. 14, pp. 1404–1411, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. W. van Werkum, C. A. K. van der Stelt, T. H. Seesing, C. M. Hackeng, and J. M. ten Berg, “A head-to-head comparison between the VerifyNow® P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention,” Journal of Thrombosis and Haemostasis, vol. 4, no. 11, pp. 2516–2518, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. R. Paniccia, E. Antonucci, A. M. Gori, et al., “Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients,” Journal of Thrombosis and Haemostasis, vol. 5, no. 9, pp. 1839–1847, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus